Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-05-14

Immunological basis of rational vaccine design for hepatitis C virus

Objetivo



The major objective of this proposal i8 to develop strategies to design a vaccine against the hepatitis C virus (HCV) through the analysis of the HCV specific immune response. In addition, the involvement of members of the combined group in vaccine development means that the necessary expertise is available to proceed rapidly from characterisation of immune responses to development of vaccine strategies. Hepatitis C virus (HCV) is an RNA virus with a high degree of sequence variability among different genotypes. It is responsible for the majority of blood borne chronic hepatitis. The prevalence of HCV infection around the world is between 0.4 and 2%. Chronic hepatitis develops in at least half the infected patients and progresses to liver cirrhosis in 20% of the chronic cases. Furthermore, most cases of hepato cellular carcinoma are caused by HCV.A first step in designing an HCV vaccine is the identification of the components involved in protective immunity. At present, little is known on the role the immune response plays in the course of HCV infection and whether antigenic variation among different HCV genotypes plays any role in the pathogenesis of hepatitis C.

We propose to characterize the immune response to the different HCV proteins inpatients with acute infection who succeed in clearing the virus and those who develop a chronic infection. In the course of these studies we will assess the importance of the immune response with respect to viral clearance and to the pathogenesis of liver disease.

To achieve these objectives we will define:
1) the antigenic specificity and effectors functions both of HLA class I and class II restricted T cell responses to HCV in the peripheral blood and, when possible, in the liver;
2) the quantitative (ELISA) and qualitative (neutralisation) aspects of the serum antibody responses to HCV.

The foregoing studies will lead to the identification of amino acid sequences (epitopes) within the various HCV antigens that are responsible for T and Bcell responses during acute and chronic HCV infection, and will establish the relationship between these responses and viral clearance and disease activity. Furthemore, we will gain knowledge on the role played by viral sequence variabil in viral persistence and disease pathogenesis. In conclusion, this is a proposal to characterize the humoral and cellular immune response to all of the known HCV-encoded antigens in an effort to delineate the factors potentially involved in viral clearance and liver disease. Characterization of the immune responses the various HCV antigens will hopefully provide the conceptual framework for the design of effective preventive strategies against HCV infection.

Ámbito científico (EuroSciVoc)

CORDIS clasifica los proyectos con EuroSciVoc, una taxonomía plurilingüe de ámbitos científicos, mediante un proceso semiautomático basado en técnicas de procesamiento del lenguaje natural. Véas: El vocabulario científico europeo..

Para utilizar esta función, debe iniciar sesión o registrarse

Programa(s)

Programas de financiación plurianuales que definen las prioridades de la UE en materia de investigación e innovación.

Tema(s)

Las convocatorias de propuestas se dividen en temas. Un tema define una materia o área específica para la que los solicitantes pueden presentar propuestas. La descripción de un tema comprende su alcance específico y la repercusión prevista del proyecto financiado.

Convocatoria de propuestas

Procedimiento para invitar a los solicitantes a presentar propuestas de proyectos con el objetivo de obtener financiación de la UE.

Datos no disponibles

Régimen de financiación

Régimen de financiación (o «Tipo de acción») dentro de un programa con características comunes. Especifica: el alcance de lo que se financia; el porcentaje de reembolso; los criterios específicos de evaluación para optar a la financiación; y el uso de formas simplificadas de costes como los importes a tanto alzado.

CSC - Cost-sharing contracts

Coordinador

AZIENDA OSPEDALIERA DI PARMA - OSPEDALE MAGGIORE
Aportación de la UE
Sin datos
Dirección
14,Via Gramsci 14
43100 PARMA
Italia

Ver en el mapa

Coste total

Los costes totales en que ha incurrido esta organización para participar en el proyecto, incluidos los costes directos e indirectos. Este importe es un subconjunto del presupuesto total del proyecto.

Sin datos

Participantes (2)

Mi folleto 0 0